Consistent with this hypothesis, we found that ATM-deficient cancer lines are more sensitive to CC-115 than ATM proficient lines, suggesting patients with ATM-deficient tumors such as breast cancer as potential patient populations for clinical development of CC-115. This evidence concerns the gene ATM and breast carcinoma.